Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2017 Apr 11;116(8):e14.
doi: 10.1038/bjc.2017.58. Epub 2017 Mar 21.

Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'

Keisuke Imafuku  1   2 , Koji Yoshino  1 , Kei Yamaguchi  1 , Satoshi Tsuboi  1 , Kuniaki Ohara  1 , Hiroo Hata  2
Affiliations
Comment

Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'

Keisuke Imafuku et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Comment in

Comment on

References

    1. Bowyer S, Prithviraj P, Lorigan P, Larkin J, McArthur G, Atkinson V, Millward M, Khou M, Diem S, Ramanujam S, Kong B, Liniker E, Guminski A, Parente P, Andrews MC, Parakh S, Cebon J, Long GV, Carlino MS, Klein O (2016) Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. Br J Cancer 114(10): 1084–1089. - PMC - PubMed
    1. Harding JJ, Pulitzer M, Chapman PB (2012) Vemurafenib sensitivity skin reaction after ipilimumab. N Engl J Med 366(9): 866–868. - PubMed
    1. Imafuku K, Yoshino K, Ishiwata K, Otobe S, Tsuboi S, Ohara K, Hata H (2015) Severe rash associated with vemurafenib administration following nivolumab therapy. J Eur Acad Dermatol Venereol 30(10): e84–e86. - PubMed
    1. Johnson DB, Wallender EK, Cohen DN, Likhari SS, Zwerner JP, Powers JG, Shinn L, Kelley MC, Joseph RW, Sosman JA (2013) Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 1(6): 373–377. - PMC - PubMed
    1. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1): 23–34. - PMC - PubMed